Expert Commentary

When Insurance Denies the Better Option, Oncologists Treat What Patients Can Afford

A hematologist-oncologist explains how coverage denials and financial toxicity quietly reshape treatment decisions before patients ever reach the pharmacy counter.

Published November 10, 2026
When Insurance Denies the Better Option, Oncologists Treat What Patients Can Afford
Dr. Leena T. Rahmat
As told to MedStory News
Dr. Leena T. Rahmat
Hematology & Oncology
View Profile
Advertisement
Website Design

The treatment plan Leena T. Rahmat recommended was straightforward: an oral immunotherapy that patients could take at home, with a less toxic profile than conventional chemotherapy. The insurer said no. The drug's cost made it ineligible for coverage, leaving the patient, newly diagnosed with non-Hodgkin lymphoma, facing thousands of dollars per month in out-of-pocket expenses. The plan changed. The patient received intravenous chemo-immunotherapy instead, a more burdensome regimen by most measures, because it was the one the system would pay for.

That kind of substitution rarely makes the chart notes. It happens somewhere between the exam room and the coverage determination, in the gap between what a physician judges to be the right clinical choice and what a patient can realistically afford. Rahmat describes it plainly: much of the cost-related adjustments she makes are driven not by clinical evidence but by what healthcare insurance carriers will and will not cover.

She now builds that reality into her initial conversations with patients.

"Upon initial counseling with the patients, I provide them with a heads-up that we may have to change the treatment plan or make minor adjustments based on costs."
It is a disclosure that reframes the nature of the physician-patient relationship before treatment even begins, not as a partnership defined solely by what medicine can do, but by what the financial architecture around it permits.

The consequences extend well past the clinical. As Rahmat puts it,

"if patients go bankrupt at medical bills, they won't be able to afford housing, food, transport, so do have to make adjustments to treatment plans so that they can live their daily lives too."
The calculus she describes is not abstract. Treatment decisions in oncology increasingly account for whether a patient can sustain both a regimen and a life outside of it.

Her proposed fix is blunt. She would

"eliminate the middleman healthcare insurance carrier, eliminate surprise bills and create transparency between what patients receive for care and how much they pay to the physicians/facilities."
Whether or not that vision is politically achievable, it names something that tends to get lost in policy debates about healthcare costs: the person absorbing the opacity of the current system is often sitting across from a physician, learning for the first time that the recommended treatment is one their coverage has decided they cannot have.

Advertisement
Patient Education Portal